Activity Stream
@moatrx
• 2 weeks ago
Posted a new blog:
US COLD AGGLUTININ DISEASE LAUNCH READINESS
US COLD AGGLUTININ DISEASE LAUNCH READINESS
Sutimlimab left 46 percent of trial patients without a hemoglobin response, yet two rival complement programs abandoned the disease after its launch.
Sutimlimab...
